Bausch + Lomb Completes Acquisition of XIIDRA
Bausch + Lomb Completes Acquisition of XIIDRA Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced…
Read MoreBausch + Lomb Completes Acquisition of XIIDRA
ew Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZAto Support Thyroid Eye Disease Patient Outcomes
ew Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes Horizon Therapeutics plc (Nasdaq: HZNP) today announced new…
GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine
GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine‘ GEDi Cube Intl Ltd. (GEDi Cube), an AI medical technology company, and Renovaro Biosciences Inc. (NASDAQ:RENB) (Renovaro), an advanced, preclinical…
Faeth Therapeutics Appoints Debbie Chirnomas, M.D., M.P.H., as Chief Medical Officer
Faeth Therapeutics Appoints Debbie Chirnomas, M.D., M.P.H., as Chief Medical Officer –Faeth Therapeutics, a clinical-stage biotechnology company targeting cancer metabolism, today announced the appointment of Debbie Chirnomas M.D., M.P.H., as…
Cimeio Therapeutics Announces Publication of Seminal Epitope Editing Work in the Journal of Experimental Medicine
Cimeio Therapeutics Announces Publication of Seminal Epitope Editing Work in the Journal of Experimental Medicine Cimeio Therapeutics, a biotechnology company that is reimagining immunotherapy with its Shielded Cell and Immunotherapy (SCIP®)…
United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs
United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the achievement of two milestones for its xenotransplantation…
Thought leaders at the Zayed Prize for Sustainable Development Forum chart paths forward to promote progress for people and planet
Thought leaders at the Zayed Prize for Sustainable Development Forum chart paths forward to promote progress for people and planet The Zayed Prize for Sustainable Development, the UAE’s pioneering prize…
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Ligand Pharmaceuticals Incorporated announced that…
Datopotamab deruxtecan demonstrated a statistically significant and clinically meaningful progression-free survival benefits in patients with HR-positive, HER2-low, or negative breast cancer in the TROPION-Breast01 Phase III trial
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low, or negative breast cancer in TROPION-Breast01 Phase III trial Positive high-level results from the TROPION-Breast01…
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer Bristol Myers Squibb today announced the…
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer Merck (NYSE: MRK), known as…
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator Vividion Therapeutics, Inc. (Vividion), announced today that it has initiated dosing of patients in a Phase…